Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole plus palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study

被引：0
|
作者：
Hurvitz, Sara A.
Quiroga, Vanesa
Park, Yeon Hee
Bardia, Aditya
Lopez-Valverde, Vanesa
Steinseifer, Jutta
Fernando, Tharu M.
Spera, Gonzalo
Xue, Cloris
Fasching, Peter A.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-06
引用
收藏
页数：3
相关论文
共 50 条
  • [31] evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane plus everolimus in patients with estrogen receptor+, HER2-locally advanced or metastatic breast cancer
    Mayer, Erica L.
    Tolaney, Sara
    Brufsky, Adam M.
    Gradishar, William
    Jhaveri, Komal
    Martin, Miguel
    Moscetti, Luca
    Vidal, Gregory
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer
    Collier, Ann
    Bardia, Aditya
    Sohn, Joo Hyuk
    Lim, Elgene
    Chavez, Marianna
    Martin, Miguel
    Martinalbo, Jorge
    Perez-Moreno, Pablo
    Moore, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [33] lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy in patients with estrogen receptor+, HER2-early breast cancer
    Schmid, Peter
    Geyer, Charles E., Jr.
    Harbeck, Nadia
    Rimawi, Mothaffar
    Hurvitz, Sara
    Martin, Miguel
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovsky, Daniil L.
    Lopez-Valverde, Vanesa
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo D.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).
    Jhaveri, Komal L.
    Boni, Valentina
    Sohn, Joohyuk
    Villanueva-Vasquez, Rafael
    Bardia, Aditya
    Schmid, Peter
    Lim, Elgene
    Patel, Jaymin M.
    Alejandro Perez-Fidalgo, Jose
    Loi, Sherene
    Im, Seock-Ah
    Kshirsagar, Smita
    Gates, Mary R.
    Bond, John
    Eng-Wong, Jennifer
    Chang, Ching-Wei
    Turner, Nicholas C.
    Lopez Miranda, Elena
    Garcia-Estevez, Laura
    Bellet, Meritxell
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
    Prat, Aleix
    Saura, Cristina
    Pascual, Tomas
    Hernando, Cristina
    Munoz, Montserrat
    Pare, Laia
    Gonzalez Farre, Blanca
    Fernandez, Pedro L.
    Galvan, Patricia
    Chic, Nuria
    Gonzalez Farre, Xavier
    Oliveira, Mafalda
    Gil-Gil, Miguel
    Arumi, Miriam
    Ferrer, Neus
    Montano, Alvaro
    Izarzugaza, Yann
    Llombart-Cussac, Antonio
    Bratos, Raquel
    Gonzalez Santiago, Santiago
    Martinez, Eduardo
    Hoyos, Sergio
    Rojas, Beatriz
    Antonio Virizuela, Juan
    Ortega, Vanesa
    Lopez, Rafael
    Celiz, Pamela
    Ciruelos, Eva
    Villagrasa, Patricia
    Gavila, Joaquin
    LANCET ONCOLOGY, 2020, 21 (01): : 33 - 43
  • [36] Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer
    Ueno, Takayuki
    Chow, Louis W. C.
    Han, Wonshik
    Huang, Chiun Sheng
    Mann, G. Bruce
    Morita, Satoshi
    Haga, Hironori
    Fakhrejahani, Elham
    Kobayashi, Takayuki
    Inoue, Kenichi
    Tokiwa, Mariko
    Suwa, Hirofumi
    Aruga, Tomoyuki
    Minamiguchi, Sachiko
    Yamada, Yosuke
    Tanabe, Yuko
    Takada, Masahiro
    Yamashita, Toshinari
    Iwata, Hiroji
    Chung, Chi-Feng
    Takahara, Sachiko
    Tokunaga, Eriko
    Imoto, Shigeru
    Lee, Eun Sook
    Sagara, Yasuaki
    Kim, Jee Hyun
    DeBoer, Richard H.
    Kim, Hyun-Ah
    Lai, Hung Wen
    Hou, Ming-Feng
    White, Michelle
    Umeyama, Yoshiko
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)
    Skriver, Signe Korsgaard
    Laenkholm, Anne-Vibeke
    Rasmussen, Birgitte Bruun
    Handler, Juergen
    Grundtmann, Bo
    Tvedskov, Tove Filtenborg
    Christiansen, Peer
    Knoop, Ann S.
    Jensen, Maj-Britt
    Ejlertsen, Bent
    ACTA ONCOLOGICA, 2018, 57 (01) : 31 - 37
  • [38] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Bingnan Zhang
    Elisa F. Long
    Breast Cancer Research and Treatment, 2019, 175 : 775 - 779
  • [40] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Zhang, Bingnan
    Long, Elisa F.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 775 - 779
12345